$TARS News

Tarsus Pharmaceuticals Files Prospectus Related To The Proposed Offer And Resale Of Up To 2.91M Shares Of Common Stock By Selling Stockholders

Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak

Tarsus (TARS) Q2 2026 Earnings Call Transcript

Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

Tarsus Pharmaceuticals Q2 Earnings Call Highlights

Tarsus joins Stargardt race to market with $800m Alkeus takeover

Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ...

Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing